Compare the Pharmacokinetics of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe

A Clinical Trial to Compare the Pharmacokinetics and Safety of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe in Healthy Male Volunteers

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02029625

Acronym

NVP-1205

Enrollment

Registered

2014-01-08

Start date

2014-02-28

Completion date

2014-03-31

Last updated

2016-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia

Brief summary

The purpose of this study is to compare the pharmacokinetics of NVP-1205 and coadministration of rosuvastatin and ezetimibe.

Detailed description

rosuvastatin and ezetimibe(anti-dyslipidemia)

Interventions

DRUGNVP-1205

rosuvastatin/ezetimibe fixed dose combination orally, once daily on Period 1 or Period 2

DRUGrosuvastatin and ezetimibe

coadministration of rosuvastatin and ezetimibe orally, once daily on Period 1 or Period 2

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

19 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy male subjects age between 19 and 55 signed informed consent

Exclusion criteria

* subjects have a history of allergy reaction of this drug or other drugs

Design outcomes

Primary

Measure	Time frame
AUClast	0-96hr

Secondary

Measure	Time frame
AUCinf	0-96hr

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026